A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

BACKGROUND: Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in patients with BRAF-mutated metastatic melanoma to improve l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Clark, Joseph I., Singh, Jatinder, Ernstoff, Marc S., Lao, Christopher D., Flaherty, Lawrence E., Logan, Theodore F., Curti, Brendan, Agarwala, Sanjiv S., Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L., Aung, Sandra, Lawson, David H.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6062934/
https://ncbi.nlm.nih.gov/pubmed/30053905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0387-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados